Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Implementation of Combined Monogenic and Polygenic Risk Disclosure for Coronary Artery Disease

1 Aug 2022

Abstract excerpt

BACKGROUND: State-of-the-art genetic risk interpretation for a common complex disease such as coronary artery disease (CAD) requires assessment for both monogenic variants-such as those related to familial hypercholesterolemia-as well as the cumulative impact of many common variants, as quantified by a polygenic score. OBJECTIVES: The objective of the study was to describe a combined monogenic and polygenic CAD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Genetic Associations and Epidemiology
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36147540
DOI: 10.1016/j.jacadv.2022.100068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Implementation of Combined Monogenic and Polygenic Risk Disclosure for Coronary Artery DiseasePMID 36147540Read ↗

Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease.Semantic proximity Read ↗

Designing to Implement Genomics Informed ASCVD Risk Assessment: Patient and Clinician Perspectives about Identifying and Managing the Underlying Causes of Severe HypercholesterolemiaSemantic proximity Read ↗

Polygenic Risk Score Implementation into Clinical Practice for Primary Prevention of Cardiometabolic Disease.Semantic proximity Read ↗

Development of an Integrated Monogenic and Polygenic Risk Assessment Tool for Coronary Artery Disease and Its Application in a Community-Based Health Care Biobank.Semantic proximity Read ↗

Communicating polygenic and non-genetic risk for atherosclerotic cardiovascular disease - An observational follow-up studySemantic proximity Read ↗

Clinical validation of a statin-benefit polygenic score using real-world cohorts of primary prevention participantsSemantic proximity Read ↗

Polygenic risk scores: how much do they add?Semantic proximity Read ↗

Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial).Semantic proximity Read ↗

Response to Polygenic Risk: Results of the MyGeneRank Mobile Application-Based Coronary Artery Disease StudySemantic proximity Read ↗

Effect of disclosing a polygenic risk score for coronary heart disease on adverse cardiovascular events: 10-year follow-up of the MI-GENES randomized clinical trialSemantic proximity Read ↗

Additive value of polygenic risk and family history for coronary heart disease risk stratification in two diverse US cohorts.Semantic proximity Read ↗

Polygenic Background Modifies Risk of Coronary Artery Disease Among Individuals With Heterozygous Familial HypercholesterolemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.